Skip to main content

Table 1 Patient baseline characteristics

From: Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Characteristics 1 L (n = 62) 2 L (n = 20)
Age, n (%)
  < 65 years 37 (59.7) 7 (35.0)
  ≥ 65 years 25 (40.3) 13 (65.0)
Median age (range), years 62 (36–85) 69 (30–80)
Sex, n (%)
 Male 43 (69.4) 15 (75.0)
 Female 19 (30.6) 5 (25.0)
ECOG PS, n (%)
 0 37 (59.7) 9 (45.0)
 1 25 (40.3) 11 (55.0)
MSKCC prognostic risk group, n (%)
 Favorable 2 (3.2) 0
 Intermediate 53 (85.5) 17 (85.0)
 Poor 7 (11.3) 3 (15.0)
IMDC prognostic risk group, n (%)
 Favorable 24 (38.7) 5 (25.0)
 Intermediate 27 (43.5) 13 (65.0)
 Poor 11 (17.7) 2 (10.0)
Median time since diagnosis of metastatic disease (range), months 2.5 (0.4–90.4) 15.0 (1.6–80.4)
Number of prior anticancer therapy lines for metastatic or locally advanced disease, n (%)
 0 62 (100.0)a 0
 1 0 19 (95.0)
 2 0 0
 3 0 0
  ≥ 4 0 1 (5.0)
PD-L1 status (≥ 1% tumor cells), n (%)
 Positive 20 (32.3) 4 (20.0)
 Negative 21 (33.9) 9 (45.0)
 Not evaluable 21 (33.9) 7 (35.0)
  1. a One patient (1.6%) received prior adjuvant therapy
  2. 1 L first-line subgroup, 2 L second-line subgroup, ECOG PS Eastern Cooperative Oncology Group performance status, MSKCC Memorial Sloan-Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, PD-L1 programmed death-ligand 1